1. Generics Bulletin
  2. >>Business
  3. >>Earnings

Leaner Teva Bolsters Margins With 2022 Expected To Be Trough Year

Generics Launches In 2022 Will ‘Affect The Second Half’ Of The Year

 
• By Dean Rudge

Keeping a keen eye on costs through a multi-pronged strategy allowed Teva to bolster its margins and direct cash flow towards debt in 2021. But revenues declined and 2022 is set to be another bumpy year for the Israeli giant’s top line.

business growth
Teva has seen its margins climb since a low in 2019 • Source: Alamy

Continued margin expansion allowed Teva to hit its bottom line and cash flow targets in 2021 amid declining revenues, including softer North America generics sales mainly due to a lack of significant product launches during the year.

Taking in the 2021 financial results overall, president and CEO Kåre Schultz insisted, “I am expecting that 2022 will be the trough year, so to speak

More from Earnings

More from Business